Selinexor, a FDA-approved XPO1 inhibitor, has shown antitumor activity in the clinic and is currently being used to treat various human tumors, including melanoma, colon cancer, glioblastoma, and small cell lung cancer40–43. Here, XPO1 is linked to melanoma.